NMPA accepts Overland ADCT BioPharma’s BLA for ZYNLONTA

The study assessed the safety and efficacy of the therapy alone in patients with refractory (r/r) diffuse large B-cell lymphoma. Credit: fernando zhiminaicela from Pixabay.